FBRX vs. NRIX, DNA, TERN, ANAB, PVLA, MGTX, SIGA, OLMA, KROS, and BCAX
Should you be buying Forte Biosciences stock or one of its competitors? The main competitors of Forte Biosciences include Nurix Therapeutics (NRIX), Ginkgo Bioworks (DNA), Terns Pharmaceuticals (TERN), AnaptysBio (ANAB), Palvella Therapeutics (PVLA), MeiraGTx (MGTX), Siga Technologies (SIGA), Olema Pharmaceuticals (OLMA), Keros Therapeutics (KROS), and Bicara Therapeutics (BCAX). These companies are all part of the "pharmaceutical products" industry.
Forte Biosciences vs. Its Competitors
Forte Biosciences (NASDAQ:FBRX) and Nurix Therapeutics (NASDAQ:NRIX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.
Forte Biosciences has a beta of 3.03, indicating that its stock price is 203% more volatile than the S&P 500. Comparatively, Nurix Therapeutics has a beta of 2.33, indicating that its stock price is 133% more volatile than the S&P 500.
Forte Biosciences has higher earnings, but lower revenue than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.
Forte Biosciences presently has a consensus target price of $68.00, suggesting a potential upside of 338.99%. Nurix Therapeutics has a consensus target price of $29.07, suggesting a potential upside of 209.93%. Given Forte Biosciences' higher possible upside, equities research analysts plainly believe Forte Biosciences is more favorable than Nurix Therapeutics.
77.6% of Forte Biosciences shares are owned by institutional investors. 5.9% of Forte Biosciences shares are owned by insiders. Comparatively, 7.4% of Nurix Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Forte Biosciences has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -234.57%. Nurix Therapeutics' return on equity of -45.26% beat Forte Biosciences' return on equity.
In the previous week, Forte Biosciences had 1 more articles in the media than Nurix Therapeutics. MarketBeat recorded 3 mentions for Forte Biosciences and 2 mentions for Nurix Therapeutics. Forte Biosciences' average media sentiment score of 0.85 beat Nurix Therapeutics' score of 0.74 indicating that Forte Biosciences is being referred to more favorably in the media.
Summary
Forte Biosciences and Nurix Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get Forte Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for FBRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding FBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Forte Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:FBRX) was last updated on 10/5/2025 by MarketBeat.com Staff
